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Abstract Headache induced by
acute exposure to a specific drug
constitutes an idiosyncratic side
effect. Metabolic imbalance
appears as the leading aetiology,
among several other hypotheses.
Either primary headaches show a
higher susceptibility to this idio-
syncratic reaction or a drug-
induced primary headache evolves
in intensity and duration, becom-
ing uncontrolled until the complete
discontinuation of the drug in con-
sideration. The goal of this study
is to describe three patients diag-
nosed with migraine and epilepsy
(both under control) who evolved
into status migrainosus after the
introduction of oxcarbazepine
(OXC), as part of a switch off
from carbamazepine (CBZ).
Twenty-four to seventy-two hours
following the switch, all patients
developed intractable headache,
despite the use of different symp-
tomatic drugs. Complete recovery
of the headache symptoms
occurred only after OXC was dis-
continued. We discuss the potential
mechanisms associated to OXC
and status migrainosus, drug-
induced headaches and uncon-
trolled headaches.
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Introduction
Headaches induced by acute substance use or exposure are
common conditions in which there is a clear relationship
between the onset of symptoms and the intake of one drug
for therapeutic purposes. The Second Edition of the
International Classification of Headache Disorders
(ICHD-II) subdivided this group in 11 subgroups [1].
Nitric oxide, phosphodiesterase inhibitors, carbon monox-
ide, alcohol, monosodium glutamate, cocaine, cannabis,
histamine and calcitonin gene-related peptide are the main
drugs that induce headaches. However, other drugs or ther-
apeutic agents may be involved, depending on various
patient susceptibility factors.
Migraineurs are physiologically and perhaps psycho-
logically hyper-responsive to a variety of internal and
external stimuli. Alcohol, food and food additives, chemi-
cal, drug ingestion and withdrawal have all been reported
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to provoke or activate migraine in susceptible individu-
als1. The association is often based on anecdotal data and
reports of adverse drug reactions. Thus, the mere use of a
given drug leading to headache does not prove causation,
because these common events happen commonly and
probably reflect a pure coincidence. Headache can be a
symptom of a systemic disease, and drugs given to treat
such a condition will be associated with headache. In acute
migraine drug trials, headache, as well as associated symp-
toms, is listed as an adverse drug reaction despite the fact
that it is a symptom of the treated disorder and not the
result of the treatment. However some acute or chronic
substance exposures have been proven to be causally relat-
ed to headache. Medications are a well known cause of
secondary headache, especially in the elderly.
A variety of drugs can induce headache (Table 1).
Interestingly, some are commonly employed as either pre-
ventive or symptomatic medications in the treatment of
migraine or other headaches [2,3]. Vasodilation and
increase of intracranial pressure are some of the putative
mechanisms underlying drug-related headaches.
Three patients in whom oxcarbazepine (OXC) is poten-
tially implicated in the development of status migrainosus
are presented. We reviewed the literature and discuss con-
cepts that may be related to such cases in the context of
uncontrolled headache and drug-induced headaches.
Materials and methods
Patient 1
A 33-year-old female was referred to the Headache Clinic due to
severe and intractable headache. She started having headaches at
the age of 10, with unilateral, pulsating headache, associated with
photophobia, phonophobia, nausea and vomiting, lasting from 6 to
18 h. Typically, the headache attacks were related to the menses and
tended to subside entirely following the use of 50 mg of sumatrip-
tan. At age 16 the patient presented with secondarily generalised
seizures. MR imaging showed a small mass on the left temporal
lobe, consistent with a dysembryoplastic neuroepithelial tumour.
She was put on carbamazepine (CBZ) and subsequently on leve-
tiracetam with poor results. CBZ (at daily dose of 1400 mg) was
switched to OXC (at daily dose of 2100 mg), as an attempt to
improve her seizure control. On day 2 of OXC a diffuse pulsating
headache of severe intensity, associated with nausea and vomiting
and aggravated by physical activity, was reported. By the time of
her evaluation at the outpatient clinic the headache had proven to be
resistant to oral sumatriptan (100 mg), IV metroclopramide, Cox-2
inhibitors, IM nonsteroid anti-inflammatory (NSAI), IV dexam-
ethasone (4 mg) and IV chlorpromazine. She was admitted for fluid
hydration. OXC was discontinued and CBZ was reintroduced lead-
ing to complete headache cessation within a 48-h period. Sodium
levels were not requested during admission.
Patient 2
A 38-year-old female was referred to the Headache Clinic due to
disabling headaches. At age 13 she started with visual and/or senso-
ry symptoms evolving gradually over approximately one hour, fol-
lowed by headache. The latter was unilateral, pulsating and moder-
ate to severe in intensity pain, lasting up to 24 h. Associated symp-
toms included nausea and vomiting. At the onset of symptoms the
attacks occurred 3 times a month but frequency had increased sig-
nificantly over the past 8 years. MR imaging showed a large vascu-
lar malformation in the right occipital lobe. An attempt at intravas-
Table 1 Drugs that may induce headache or worsen pre-existing headache [1-3]
Acetazolamine Didanosine Isoniazid Perhexiline
Ajmaline Dihydralazine Meprobamate Primidone
Amantadine Dihydroergotamine Methaqualone Propranolol
Antihistaminics Dipyridamole Metronidazole Prostacyclines
Atenolol Disopyramide Metoprolol Ranitidine
Barbiturates Disulfiram Morphine Rifampicin
Beta-interferon Ergotamine Nalidixic acid Sildenafil
Bromocriptine Ethynilestradiol Nifedipine Tamoxifen
Caffeine Gestagens Nitrofurantoin Tetracycline
Calcium antagonists Glycerol trinitrate Nitrates Theophylline
Carbimazol Glycosides Non steroidal anti-inflammatory Thiamazole
Chinidine Griseofulvin Octreotide Trimethoprim+sulfamethoxazole
Chloroquine Guanathidine Oestrogens Triptans
Cimetidine Immunoglobulins Omeprazole Verapamil
Clofibrate Indomethacin Ondansetron Vitamin A
Codeine Interferons Paroxitine Oxcarbazepine
Danazol Isosorbide dinitrate Pentoxifylline
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cular treatment (embolisation) was complicated by intracerebral
haemorrhage (including intraventricular bleeding) that required
surgical drainage and the placement of a ventriculoperitoneal shunt.
Shortly after the procedures, simple partial seizures with secondary
generalisation developed. She was put on CBZ 600 tid and
clobazam 10 mg/day. In spite of adequate seizure control the patient
complained of dyspepsia and weight gain. CBZ was replaced by
OXC 1200 mg (daily dosage). Hours after the switch the headache
transformed into daily, severe, bilateral, pulsating pain, accompa-
nied by nausea and vomiting, photo- and phonophobia, increasing
with physical effort. The patient was admitted and treated with IM
NSAI, IV metroclopramide, IV dexamethasone and IV chlorpro-
mazine with virtually no results. Sodium levels were not obtained.
OXC was withdrawn and CBZ was re-established, leading to com-
plete remission of the symptoms within a 3-day period.
Patient 3
A 30-year-old female was referred to the Headache Clinic due to
intractable epilepsy. Headaches started at age 12, with bilateral, pul-
sating and severe pain, associated with nausea, vomiting, photo-
and phonophobia, lasting up to 32 h. Headaches occurred twice a
month and were easily treated by oral isometheptene. History was
also positive for primary generalised epilepsy. Interestingly, the
patient was seizure-free on 1200 mg (daily dose) of CBZ. For
unclear reasons the primary physician decided to switch the patient
to OXC 1800 mg (daily dose), after which she developed severe,
pulsating, holocranial pain, increased by movement and associated
with nausea, vomiting, photo- and phonophobia. IM metroclo-
pramide, IV ketoprofen and SC sumatriptan were tried at the outpa-
tient clinic. The patient was admitted and tried on IV dexametha-
sone and IV chlorpromazine with no results. OXC was discontinued
and CBZ reintroduced. The pain subsided over a 3-day period.
All subjects provided written informed consent, as required
by the appropriate local committee (Human Ethical committee of
Universidade Federal do Paraná) on the protection of research
subjects.
Discussion
We report on three cases of OXC-induced difficult-to-con-
trol pain suggesting status migrainosus and subsequently
bona fide intractable headache. We felt that an association
between both headache and OXC, status migrainosus and
OXC and intractable headache and OXC could be clearly
established, as symptoms developed shortly after the intro-
duction of the drug and completely subsided following its
withdrawal.
OXC is a new antiepileptic (AED), available since
1990, which has been proven effective in the treatment of
partial seizures [4]. Hyponatraemia, defined as serum sodi-
um concentration of 134 mEq/l or less, tends to occur in
about 30% of OXC-treated patients and may be severe
(i.e., serum sodium below 128 mEq/l) in 12% of the
patients [5]. This effect is thought to be mediated by either
a direct action of the drug on the renal collecting tubules
or an enhancement of their responsiveness to circulating
antidiuretic hormone [6].
Serum sodium levels maybe relevant, as shown in a
recent paper describing OXC-induced headache [7]. That
was a single case in which hyponatraemia (131 mEq/l) was
detected during the course of the headache and improved
(141 mEq/l) after OXC withdrawal, when the patient
became free of symptoms. Hyponatraemia manifests itself
by headache, dizziness and lethargy, though such symp-
toms are rarely seen with serum sodium levels above 125
mEq/l8. However, hyponatraemia might induce headache
in predisposed subjects before the appearance of overt
encephalopathy, particularly if associated with other
drugs. In the previously described case of OXC-induced
headache the patient had a positive family history for
headache (probably migraine headache) [7].
OXC was evaluated as preventive therapy in patients
suffering from migraines in a multicentre, double-blind,
randomised, placebo-controlled, parallel-group study. The
double-blind treatment between the OXC and placebo
groups was not statistically significant. In this study,
headache, as a side effect in migraine patients, was report-
ed in 5.9% of the cases [9]. Regretfully, clinical features of
this specific population were not described in the study.
The IHS defines status migrainosus as an attack of
migraine, the headache phase of which last more than 72 h
whether it is treated or not [1]. Factors responsible for trig-
gering status migrainosus include emotional stress, depres-
sion, abuse of medications, anxiety, diet, hormonal factors
and multiple nonspecific factors [10]. Status migrainosus
may be secondary to an acute neurologic disorder.
However, acute central nervous system events can trigger
an otherwise typical migraine.
Patients with status migrainosus can evolve to
intractable headache. Intractable is defined as uncontrol-
lable, refractory or unmanageable [11], and thus the term
can be used for a headache that requires either acute or
preventive treatment [12]. Recently, criteria of uncon-
trolled headache have been suggested for preventive treat-
ment: failure of at least four classes, where three should
come from 1–4 groups of medicines, including (1) ‚-block-
ers; (2) anticonvulsants; (3) calcium channel blockers; (4)
tricyclic antidepressants; (5) other treatments with at least
one positive randomised controlled trial; (6) non-steroidal
anti-inflammatory drugs; and (7) metabolic enhancers,
such as vitamin B2 or coenzyme Q10.
Although acute intractable headache has not been sug-
gested until the present moment, we used this term to refer
to the three cases that used different lines of the acute
treatment for migraine with no success, for a period over
72 h. Only after the OXC was discontinued did the pain
subside, reinforcing a direct relationship between OXC
and pain in those cases.
When a new headache occurs for the first time in close
temporal relation to substance exposure, it is coded as a
secondary headache attributed to the substance. This is
also true if the headache has the characteristics of
migraine, tension-type headache or cluster headache.
When a pre-existing, primary headache, as in our cases, is
made worse in close temporal relation to substance expo-
sure, there are two possibilities, and careful judgement is
required [1]. The patient can either be given only the diag-
nosis of the pre-existing primary headache or be given
both this diagnosis and the diagnosis of headache attrib-
uted to the substance. A very close temporal relationship to
the substance exposure, a marked worsening of the pre-
existing headache, very good evidence that the substance
can aggravate the primary headache and, finally, improve-
ment or resolution of the headache after termination of
effect of the substance [1] are required. Headaches attrib-
uted to medication are not very well defined in the litera-
ture but most are dull, continuous, diffuse and moderate to
severe intensity. The diagnostic criteria are described in
Table 2.
We devised two working hypothesis regarding our 3
cases. First, OXC-induced headache and the pain were
directly related to acute medication and symptoms were
exclusively related to OXC. Secondly, OXC-induced
headache and the pain were directly related to acute medica-
tion, however, the patients, who had a primary headache his-
tory – in these cases, migraine – developed a migraine attack
that progressed to status migrainosus, and finally intractable
headache (Fig. 1). We will provide substantial evidence for
both hypotheses.
Symptoms may be related exclusively to OXC as their
onset took place one hour after its introduction and
patients experienced complete remission within 72 h fol-
lowing OXC withdrawal. Standard medications for the
treatment of acute migraine attacks failed to resolve the
symptoms in all patients. Interestingly enough, headaches
induced by medication are generally not severe in intensi-
ty and the nausea and vomiting promptly subside. That was
not the case in our patients, who required admission, IV
fluids and IV metoclopramine.
OXC evolving into status migrainosus is suggested by
the presence of severe persistent headache, often associat-
ed with nausea and vomiting, seen in all our patients.
It seems that status migrainosus could be induced by
OXC as this drug produces hyponatraemia, an atypical situ-
ation of the brain. Unfortunately we are unable to provide
complete data in that regard, as sodium levels were not mon-
itored during admission in all cases. The literature suggests
that in newly diagnosed cases of status migrainosus a sec-
ondary aetiology must be sought after and OXC may be the
case in our patients. The interactions of OXC and other med-
icines utilised in our patients could also explain the induced
status migrainosus, but the relationship between headache
and OXC was seemingly clear.
Fig. 1 Sequence of the events of OXC-induced headache and status
migrainosus
Table 2 International Headache Society classification for headache
as an acute adverse event attributed to medication used for other
indications [1]
8.1.10. Diagnostic criteria:
A. Headache fulfilling criteria C and D
B. Use of a medication for a therapeutic indication other than headache
C. Headache develops within minutes to hours after use
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